| Ziphius Vaccines N.V.. (6/9/22). "Press Release: Ziphius Vaccines and University of Antwerp Announce Collaboration Agreement for Optimized Delivery of saRNA-based Vaccines & Therapeutics". |
2022-06-09 |
| Ziphius Vaccines N.V.. (5/25/21). "Press Release: Ziphius Vaccines Raises €29.3M in Oversubscribed Series A Financing". |
2021-05-25 |
| Xenikos B.V.. (5/15/18). "Press Release: Dutch Company Xenikos Secures USD 30 Million in Series B Financing". Nijmegen. |
2018-05-15 |
| Wacker Chemie AG. (7/28/20). "Press Release: Wacker Invests in Amsterdam Biotech Site". Munich & Amsterdam. |
2020-07-28 |
| Wacker Chemie AG. (12/14/21). "Press Release: Wacker and CordenPharma Develop Solutions for Formulating Lipid Nanoparticles Expanding Their Portfolio for Advanced Medicines". Munich & Luxembourg. |
2021-12-14 |
| Vlerick Business School. (2/23/17). "Press Release: Vlerick and KU Leuven Found the Health Sciences & Business Institute Together". |
2017-02-23 |
| VitriCell S.A.. (1/23/18). "Press Release: VitriCell Raises Over €1 Million ($1.2M) in Series A Funding". Liège. |
2018-01-23 |
| Vitestro. (3/21/23). "Press Release: Vitestro Raises EUR 12 Million in Series A Financing Round to Bring the World's First Autonomous Blood Drawing Device to the European Market". Utrecht. |
2023-03-21 |
| ViroVet N.V.. (1/27/17). "Press Release: Dr George Gunn, Former CEO of Novartis Animal Health, Appointed as Chairman at ViroVet". Leuven. |
2017-01-27 |
| ViroVet N.V.. (1/10/17). "Press Release: ViroVet Successfully Raises €5 Million in Series A Funding". |
2017-01-10 |
| Virometix AG. (3/12/20). "Press Release: Virometix Announces Initiation of Phase 1 Clinical Trial with Its V-306 Vaccine Candidate". Schlieren. |
2020-03-12 |
| Vico Therapeutics B.V.. (7/29/20). "Press Release: Biotech Vico Therapeutics Raises $31 Million (€27 Million) in Series A Financing Round to Advance Therapies for Rare Central Nervous System Diseases". Leiden. |
2020-07-29 |
| VIB, Flanders Interuniversity Institute of Biotechnology. (4/20/22). "Press Release: Christine Durinx Joins VIB as Co-Managing Director". |
2022-04-20 |
| VIB, Flanders Interuniversity Institute of Biotechnology. (3/24/17). "Press Release: VIB and DNAlytics Team Up to Develop Non-invasive Colorectal Cancer Screening Test". |
2017-03-24 |
| VIB, Flanders Interuniversity Institute of Biotechnology. (12/11/17). "Press Release: New VIB Start-up Aelin Therapeutics Secures 27m € to Exploit Its Proprietary Pept-in Protein Knockdown Platform". |
2017-12-11 |
| Vesalius Biocapital Partners Sàrl. (6/25/19). "Press Release: Vesalius Biocapital III Announces Final Close of EUR 120 Million Fund". Strassen, Luxembourg. |
2019-06-25 |
| Vesalius Biocapital Partners Sàrl. (5/18/17). "Press Release: Vesalius Biocapital Announces First Close of Its Third Fund". Bertrange. |
2017-05-18 |
| Vésale Bioscience. (1/17/22). "Press Release: Vésale Bioscience Receives €1.8M Grant from European Innovation Council for PhageDiag Project". Namur. |
2023-01-17 |
| Verve Capital Partners AG (Verve Ventures). (6/24/22). "Press Release: Verve Ventures Launches Investment Fund to Support Portfolio Companies". |
2022-06-24 |
| VectorY Therapeutics B.V.. (3/20/23). "Press Release: VectorY Appoints Michael Wyzga as CFO and Adds Jean Franchi to Its Board of Directors". Amsterdam. |
2023-03-20 |
| VectorY Therapeutics B.V.. (11/13/23). "Press Release: VectorY Raises €129 Million ($138 Million) Series A Financing to Advance Vectorized Antibody Programs in Neurodegenerative Diseases". Amsterdam. |
2023-11-13 |
| VectorY B.V.. (6/15/21). "Press Release: VectorY Strengthens Leadership with Appointments of New CEO and CTO". Amsterdam. |
2021-06-15 |
| VectorY B.V.. (6/15/21). "Press Release: VectorY Raises €31 Million in Seed Financing to Develop Next-Generation Gene Therapies Aimed at Muscular and CNS Disorders". Amsterdam. |
2021-06-15 |
| VectorY B.V.. (11/8/22). "Press Release: VectorY Appoints Sander van Deventer as CEO and Makes Key Appointments to Its Leadership Team". Amsterdam. |
2022-11-08 |
| VarmX B.V.. (7/8/20). "Press Release: VarmX Raises €32 million in Series B Financing to Develop Innovative Reversal Agent for the Treatment and Prevention of Severe Bleeding in Patients on Oral Anticoagulants". Leiden. |
2020-07-08 |
| VarmX B.V.. (7/2/18). "Press Release: VarmX Raises € 12.5 Million to Develop Modified Blood Coagulation Factor X for Treating Severe Bleeding in Patients Using Anti-Coagulants". Leiden. |
2018-07-02 |
| VarmX B.V.. (6/27/17). "Press Release: VarmX Raises Seed Capital for Development of Modified Blood Coagulation Factor X". Leiden. |
2017-06-27 |
| VarmX B.V.. (5/25/23). "Press Release: VarmX Raises €30 Million Series B2 Financing for IND Approval and Preparations for Pivotal Trial". Leiden. |
2023-05-25 |
| VarmX B.V.. (1/31/23). "Press Release: VarmX Appoints Paul Roos as Chief Financial Officer". Leiden. |
2023-01-31 |
| V-Bio Ventures. (3/31/22). "Press Release: V-Bio Ventures Raises EUR 110 Million for its Second Fund and Expands Team". Ghent. |
2022-03-31 |
| V-Bio Ventures. (2/4/21). "Press Release: First Closing of V-Bio Fund 2 Is Announced at EUR 78 Million". Ghent. |
2021-02-04 |
| Univercells S.A.. (9/12/17). "Press Release: Univercells Appoints Douglas A. Neugold as Chairman of Its Board of Directors". Brussels. |
2017-09-12 |
| Univercells S.A.. (7/16/18). "Press Release: Univercells Raises €16 Million in Series B Financing Round Led by Global Health Investment Fund". Brussels & New York, NY. |
2018-07-16 |
| Univercells S.A.. (6/25/18). "Press Release: Univercells Appoints Christian Borgniet as Chief Operating Officer". Brussels. |
2018-06-25 |
| Univercells S.A.. (5/5/20). "Press Release: Launch of Univercells Technologies for Intensified, Automated Technologies". |
2020-05-05 |
| Univercells S.A.. (3/15/21). "Press Release: Univercells, Univercells Technologies and Gamma Biosciences Announce Mathias Garny as New CEO of Univercells Technologies". Brussels. |
2021-03-15 |
| Univercells S.A.. (2/18/20). "Press Release: Univercells Secures up to €50M Investment from KKR Platform to Speed Delivery of Manufacturing Technologies". Brussels. |
2020-02-18 |
| Univercells S.A.. (12/17/20). "Press Release: Univercells Holding Raises €70 Million in Series C Financing". Brussels. |
2020-12-17 |
| Univercells S.A.. (12/15/17). "Press Release: Univercells Secures €3m Series A2 Funding". Gosselies. |
2017-12-15 |
| Univercells S.A.. (10/3/19). "Press Release: Univercells Boosted by EUR 20m European Financing to Accelerate the Delivery of Its Vaccine Portfolio". Brussels. |
2019-10-03 |
| Univercells S.A.. (10/19/22). "Press Release: Univercells Raises € 44 Million in First Close of Its Series D". Brussels. |
2022-10-19 |
| Uniqure N.V.. (9/5/19). "Press Release: Uniqure Announces Pricing of its Public Offering". Lexington, MA & Amsterdam. |
2019-09-05 |
| Uniqure N.V.. (9/4/19). "Press Release: Uniqure Announces Proposed Public Offering". Lexington, MA & Amsterdam. |
2019-09-04 |
| Uniqure N.V.. (9/3/19). "Press Release: Uniqure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B". Lexington, MA & Amsterdam. |
2019-09-03 |
| Uniqure N.V.. (8/8/18). "Press Release: Uniqure Announces Second Quarter 2018 Financial Results and Highlights Company Progress". Lexington, MA & Amsterdam. |
2018-08-08 |
| Uniqure N.V.. (8/23/18). "Press Release: Uniqure Announces First Patient Treated in Dose-confirmation Study of AMT-061 in Patients with Hemophilia B". Lexington, MA & Amsterdam. |
2018-08-23 |
| Uniqure N.V.. (8/20/19). "Press Release: Uniqure Announces Leadership Promotions and Executive Transition". Lexington, MA & Amsterdam. |
2019-08-20 |
| Uniqure N.V.. (7/31/17). "Press Relase: Uniqure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B". Lexington, MA & Amsterdam. |
2017-07-31 |
| Uniqure N.V.. (6/24/20). "Press Release: Uniqure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy". Lexington, MA & Amsterdam. |
2020-06-24 |
| Uniqure N.V.. (6/22/21). "Press Release: Uniqure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)". Lexington, MA, Amsterdam & Paris. |
2021-06-22 |
| Uniqure N.V.. (6/17/20). "Press Release: Uniqure Announces the Appointment of Leonard E. Post, Ph.D. to Its Board of Directors". Lexington, MA & Amsterdam. |
2020-06-17 |
| Uniqure N.V.. (6/13/18). "Press Release: Uniqure Announces New Appointments to its Board of Directors". Lexington, MA & Amsterdam. |
2018-06-13 |
| Uniqure N.V.. (5/9/17). "Press Release: Uniqure Announces First Quarter 2017 Financial Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam. |
2017-05-09 |
| Uniqure N.V.. (5/3/18). "Press Release: Uniqure Announces Pricing of its Public Offering". Lexington, MA & Amsterdam. |
2018-05-03 |
| Uniqure N.V.. (5/15/23). "Press Release: Uniqure Announces Sale of Royalty Interest in Hemgenix for up to $400 Million". Lexington, MA & Amsterdam. |
2023-05-15 |
| Uniqure N.V.. (5/10/19). "Press Release: Uniqure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B". Lexington, MA & Amsterdam. |
2019-05-10 |
| Uniqure N.V.. (5/1/18). "Press Release: Uniqure Announces Proposed Public Offering". Lexington, MA & Amsterdam. |
2018-05-01 |
| Uniqure N.V.. (5/1/17). "Press Release: Uniqure Announces Company Presentations at Upcoming May Conferences". Lexington, MA & Amsterdam. |
2017-05-01 |
| Uniqure N.V.. (4/8/19). "Press Release: Uniqure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease". Lexington, MA & Amsterdam. |
2019-04-08 |
| Uniqure N.V.. (4/30/18). "Press Release: Uniqure Announces First Quarter 2018 Financial Results and Highlights Company Progress". Lexington, MA & Amsterdam. |
2018-04-30 |
| Uniqure N.V.. (4/29/19). "Press Release: Uniqure Announces First Quarter 2019 Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam. |
2019-04-29 |
| Uniqure N.V.. (4/26/17). "Press Release: Uniqure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at CHDI’s 12th Annual Huntington's Disease Therapeutics Conference". Lexington, MA & Amsterdam. |
2017-04-26 |
| Uniqure N.V.. (4/25/17). "Press Release: Uniqure Receives European Medicines Agency Priority Medicines (PRIME) Designation for AMT-060 in Hemophilia B". Lexington, MA & Amsterdam. |
2017-04-25 |
| Uniqure N.V.. (4/20/17). "Press Release: Uniqure Announces It Will Not Seek Marketing Authorization Renewal for Glybera in Europe". Lexington, MA & Amsterdam. |
2017-04-20 |
| Uniqure N.V.. (3/2/20). "Press Release: Uniqure Announces 2019 Financial Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam. |
2020-03-02 |
| Uniqure N.V.. (3/2/20). "Press Release: Uniqure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters". Lexington, MA & Amsterdam. |
2020-03-02 |
| Uniqure N.V.. (3/1/17). "Press Release: Uniqure Announces Presentations at Upcoming March Conferences". Lexington, MA & Amsterdam. |
2017-03-01 |
| Uniqure N.V.. (2/8/19). "Press Release: Uniqure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B". Lexington, MA & Amsterdam. |
2019-02-08 |
| Uniqure N.V.. (2/6/17). "Press Release: Uniqure Announces Presentations at Upcoming February Conferences". Lexington, MA & Amsterdam. |
2017-02-06 |
| Uniqure N.V.. (2/28/19). "Press Release: Uniqure Announces 2018 Financial Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam. |
2019-02-28 |
| Uniqure N.V.. (12/9/21). "Press Release: Uniqure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B". Lexington, MA, Amsterdam & King of Prussia, PA. |
2021-12-09 |
| Uniqure N.V.. (12/21/20). "Press Release: uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program". Lexington, MA & Amsterdam. |
2020-12-21 |
| Uniqure N.V.. (11/22/22). "Press Release: Uniqure Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B". Research Triangle Park, NC. |
2022-11-22 |
| Uniqure N.V.. (10/6/17). "Press Release: uniQure Announces FDA Orphan Drug Designation for AMT-130 in Huntington’s Disease". Lexington, MA & Amsterdam. |
2017-10-06 |
| Uniqure N.V.. (10/28/19). "Press Release: Uniqure Announces Third Quarter 2019 Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam. |
2019-10-28 |
| Uniqure N.V.. (10/27/17). "Press Release: Uniqure Announces Closing of its Public Offering". Lexington, MA & Amsterdam. |
2017-10-27 |
| Uniqure N.V.. (10/24/17). "Press Release: Uniqure Announces Pricing of its Public Offering". Lexington, MA & Amsterdam. |
2017-10-24 |
| Uniqure N.V.. (10/23/17). "Press Release: Uniqure Announces Proposed Public Offering". Lexington, MA & Amsterdam. |
2017-10-23 |
| Uniqure N.V.. (10/19/17). "Press Release: Uniqure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family Providing Broad Protection of the Hyperactive Padua Variant of Factor IX (FIX-Padua)". Lexington, MA & Amsterdam. |
2017-10-19 |
| Uniqure N.V.. (10/19/17). "Press Release: Uniqure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018". Lexington, MA & Amsterdam. |
2017-10-19 |
| Uniqure N.V.. (10/18/17). "Press Release: Uniqure Presents New Preclinical Data on AMT-130 in Huntington's Disease at the ESGCT 25th Anniversary Congress in Berlin". Lexington, MA & Amsterdam. |
2017-10-18 |
| Uniqure N.V.. (1/31/23). "Press Release: uniQure and Apic Bio Enter into Global Licensing Agreement for APB-102, a Clinical Stage Gene Therapy for Patients with ALS Caused by Mutations in SOD1". Lexington, MA, Amsterdam & Cambridge, MA. |
2023-01-31 |
| Uniqure N.V.. (1/25/17). "Press Release: Uniqure Appoints Alexander Kuta as Senior Vice President of Regulatory Affairs". Lexington, MA & Amsterdam. |
2017-01-25 |
| Uniqure N.V.. (1/22/19). "Press Release: Uniqure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington’s Disease". Lexington, MA & Amsterdam. |
2019-01-22 |
| UCB S.A.. (7/13/18). "Press Release: UCB and Amgen Resubmit Biologics Licence Application (BLA) for Evenity (Romosozumab) to the U.S. FDA". Brussels & Thousand Oaks, CA. |
2018-07-13 |
| UCB S.A.. (4/9/19). "Press Release: FDA Approves Evenity (Romosozumab) for the Treatment Of Osteoporosis in Postmenopausal Women at High Risk for Fracture". Brussels. |
2019-04-09 |
| UCB S.A.. (4/5/18). "Press Release: UCB Strengthens Research Capabilities with Acquisition of Element Genomics, a Duke University Biotech Spin-off". Brussels. |
2018-04-05 |
| UCB S.A.. (4/27/18). "Press Release: UCB Announces Positive CHMP Opinion for Cimzia (certolizumab pegol) in Patients with Moderate-to-Severe Plaque Psoriasis". Brussels. |
2018-04-27 |
| UCB S.A.. (4/25/18). "Press Release: UCB First Three Months Interim Report 2018. UCB Tracking Well towards Full Year Financial Outlook". Brussels. |
2018-04-25 |
| UCB S.A.. (4/20/18). "Press Release: UCB to Expand Epilepsy Portfolio with Strategic Acquisition of Midazolam Nasal Spray from Proximagen". Brussels. |
2018-04-20 |
| UCB S.A.. (3/9/23). "Press Release: UCB’s Board of Directors Appoints Jonathan Peacock as New Chair". Brussels. |
2023-03-09 |
| UCB S.A.. (3/9/23). "Press Release: Cancer Research UK Signs Multi-Project Collaboration with UCB to Advance Oncology Antibody Candidates". Brussels & London. |
2023-03-09 |
| UCB S.A.. (3/9/20). "Press Release: UCB Announces Appointment of Sandrine Dufour as New Chief Financial Officer". Brussels. |
2020-03-09 |
| UCB S.A.. (3/15/23). "Press Release: Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease". Brussels & Somerville, MA. |
2023-03-15 |
| UCB S.A.. (3/1/19). "Press Release: New Data Affirms Strength of UCB Immuno-Dermatology Portfolio". Brussels. |
2019-03-01 |
| UCB S.A.. (2/28/19). "Press Release: UCB Full Year Report 2018. 2018 Marks the Fifth Consecutive Year of Profitable Growth, Intensifying Investment in UCB’s Strong Pipeline". Brussels. |
2019-02-28 |
| UCB S.A.. (2/15/19). "Press Release: UCB Builds on Its R&D Footprint to Form a Research Satellite Facility within King’s College London". Brussels & Slough. |
2019-02-15 |
| UCB S.A.. (2/11/19). "Press Release: UCB and Epilepsy Society Announce Pioneering UK Genomics R&D collaboration". Slough & Brussels. |
2019-02-11 |
| UCB S.A.. (2/1/18). "Press Release: UCB and Investor Syndicate Led by Novo Seeds Launch Syndesi Therapeutics to Develop Novel Therapeutics for Cognitive Disorders". Brussels. |
2018-02-01 |
| UCB S.A.. (12/2/21). "Press Release: UCB Announces Global Partnership to Bring Disease-modifying Therapies to People Living with Parkinson’s Disease". Brussels. |
2021-12-02 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo.svg){kind=logo}
Source
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
